BACKGROUND: Myoinositol and D-chiroinositol improve insulin resistance in women with obesity and gestational diabetes and in postmenopausal women with metabolic syndrome. We previously reported that offspring born to hypertensive dams lacking endothelial nitric oxide synthase and fed a high-fat diet develop metabolic-like syndrome phenotype. OBJECTIVE: The objective of the study was to investigate the effect of a mixture of myoinositol/D-chiroinositol supplementation during pregnancy on the maternal metabolic profile in pregnancies complicated by the metabolic-like syndrome and obesity using a pregnant mouse model. STUDY DESIGN: Female heterozygous endothelial nitric oxide synthase e/þ mice with moderate hypertension were placed on a high-fat diet for 4 weeks to induce a metabolic-like syndrome phenotype. Similarly, wild-type C57BL/6 mice were placed on a high-fat diet for 4 weeks to induce a murine obesity model. Mice were then bred with wild-type males. On gestational day 1, dams were randomly allocated to receive either a mixture of myoinositol/D-chiroinositol in water (7.2/0.18 mg/mL, respectively) or water as control (placebo). At term (gestational day 18), maternal weights, systolic blood pressure, and a glucose tolerance test were obtained. Dams were then killed; pups and placentas were weighed and maternal blood collected. Serum levels of metabolic biomarkers relevant to diabetes and obesity (ghrelin, gastric inhibitory peptide, glucagon-like peptide 1, glucagon, insulin, leptin, resistin) were measured by a multiplex enzyme-linked immunosorbent assay. Analysis was done comparing metabolic-like syndrome-myoinositol/D-chiroinositoletreated vs metabolic-like syndromeenontreated mice and obese-myoinositol/ D-chiroinositoletreated vs obese nontreated mice. RESULTS: Mean systolic blood pressure was lower in metabolic-like syndrome pregnant mice treated with myoinositol/D-chiroinositol
M
etabolic syndrome and obesity are growing causes of morbidity and mortality worldwide. Metabolic syndrome is a major risk factor for cardiovascular disease and is defined by the National Institutes of Health by having at least 3 of the following conditions: hypertension, elevated fasting plasma glucose, central obesity, elevated triglycerides, or low high-density lipoprotein cholesterol. 1, 2 Metabolic syndrome etiopathogenesis and long-term consequences are still largely unknown, and preventive strategies have not yet been identified. 3 The impact of metabolic syndrome and obesity during pregnancy is substantial: indeed, all metabolic changes that develop during pregnancy have wellknown effects on not only maternal and fetal health during pregnancy, but they also act as a catalyst for future health throughout later life. 4, 5 Epidemiological and animal studies have shown that pregnancies complicated by metabolic syndrome and obesity are at risk for premature cardiovascular disease, gestational diabetes, and preeclampsia and predispose the offspring to an increased risk of cardiovascular and metabolic disease later in life. [6] [7] [8] Inositols are a family of simple carbohydrates naturally found in several foods. Inositols exist in 9 possible stereoisomers, 2 of which are predominantly found in eukaryotic cells: myoinositol and D-chiroinositol. 9 The exact molecular mechanisms of action of Myoinositol is the precursor of inositol triphosphate, a second messenger, responsible for the regulation of many hormones such as insulin, thyroid-stimulating hormone, and follicle-stimulating hormone. The activation of phospholipid-containing myoinositol by insulin activates glucose transporters, such as glucose transporter-4, and increases the cell membrane permeability to glucose, which gets into the cell and is immediately available as substrate. 10 D-chiroinositol is the conversion product of myoinositol, by an epimerization reaction, which is unidirectional and insulin dependent.
11 D-chiroinositol, different from myoinositol, is able to determine the intracellular accumulation of glucose (ie, glycogen synthesis).
So both stereoisomers are considered to play a key role in the insulin pathway, acting synergistically as insulin-sensitizing agents through the enhancement of glucose peripheral tissue uptake and glycogen synthesis. 12 In vivo animal 13, 14 and human studies [15] [16] [17] [18] [19] demonstrated that inositol supplementation during pregnancy improve the glucose profile and reduces the adverse effects of hyperglycemia. Moreover, myoinositol supplementation was proven to reduce insulin resistance in postmenopausal women with metabolic syndrome and in women with polycystic ovary syndrome, a metabolic and endocrine disorder associated with insulin resistance. 12 However, to the best of our knowledge, the inositol supplementation effect has never been investigated in pregnancies complicated by metabolic syndrome. Moreover, most of the studies in pregnant women focus on the effect of myoinositol supplementation alone, whereas mounting evidence in polycystic ovary syndrome studies suggest that the administration of combined myoinositol/D-chiroinositol at the physiological plasma ratio (40:1) ensures better clinical results, such as the reduction of insulin resistance and cardiovascular risk parameters. 20 Thus, our aim was to evaluate the effect of natural compounds, such as myoinositol and D-chiro inositol, used as a mixture, to treat pregnancies complicated by obesity and metabolic syndrome, which represent different degrees of a similar metabolic disorder. We hypothesized that myoinositol/ D-chiroinositol treatment improves the abnormal maternal metabolic profile in a pregnant mouse model of either metabolic-like syndrome or obesity. The metabolic profile improvement seen with myoinositol/D-chiroinositol treatment could also translate into positive long-term maternal and fetal health.
To achieve our aim, we used wellcharacterized mice models of obesity and metabolic syndrome that will allow identifying the best target population for a myoinositol/D-chiroinositol treatment in pregnancies with metabolic abnormalities. We previously reported that heterozygous mice lacking endothelial nitric oxide synthase gene and born to hypertensive mothers, 21 endothelial nitric oxide synthase e/þ , when fed a high-fat diet for at least 4 weeks, develop metabolic-like syndrome phenotype such as obesity, glucose intolerance, elevated systolic blood pressure, low high-density lipoprotein, high insulin, and low adiponectin levels compared with their counterpart fed a control diet. 22 Furthermore, wild-type C57BL/6J female mice fed an obesogenic diet from weaning for 4 consecutive weeks show diet-induced obesity. 23 
Materials and Methods Animals
Female and male mice, homozygous for disruption of the eNOS gene (endothelial nitric oxide synthase-knockout e/e , strain B6.129P2, stock number 002684) and their age-matched wild-type controls (strain C57BL/6J, stock number 000664) were purchased from Jackson Laboratory (Bar Harbor, ME) at 6 weeks of age. 21, 24 and fed an obesogenic diet for 4 consecutive weeks after weaning ( Figure 1 ). 22 At 7e8 weeks of age, nonpregnant endothelial nitric oxide synthase e/þ females were bred with wild-type males. At gestational day 1 of pregnancy, determined by the presence of a vaginal plug after overnight exposure to male breeders, metabolic-like syndrome dams were randomly allocated to receive either a mixture of myoinositol/Dchiroinositol dissolved in water (see next paragraph for concentrations) or plain water, as placebo (control group) ( Figure 1 ).
Obesity mouse model
To induce the obesity phenotype (Figure 1 ), wild-typeeC57BL/6J female mice were fed an obesogenic diet from weaning for 4 consecutive weeks. 23 Then at 7e8 weeks of age, obese females were bred with wild-type males and starting from gestational day 1, obese mice were randomly allocated to receive either a mixture of myoinositol/D-chiroinositol dissolved in water (see next paragraph for concentrations) or plain water, as placebo (control group).
Obesogenic diet
Both models, endothelial nitric oxide synthase e/þ eheterozygous and wildtype females offspring, were allocated to an obesogenic diet, high-fat diet (D12492, 60% of fat) until 7e8 weeks of life to induce the metabolic-like SMFM Papers ajog.org syndrome and obesity phenotypes, respectively. The high-fat diet was maintained during the whole pregnancy until animals were killed at term, on gestational day 18. Daily food consumption was estimated by subtracting the total amount of food left on the grid from the initial weight of food supplied.
Inositol supplementation during pregnancy
The myoinositol/D-chiroinositol mixture corresponds to the physiological plasma ratio of myoinositol and Dchiroinositol equal to 40:1, which has been proven to be the most effective. 20 On gestational day 1, metabolic-like syndrome and obese mice were randomly allocated to receive either a mixture of myoinositol/D-chiroinositol dissolved in water (7.2/0.18 mg/mL, respectively, based on previous animals 13, 14 and human [15] [16] [17] [18] [19] studies) or plain water as placebo.
Considering that blood volume during pregnancy physiologically shows a 20% increase compared with the nonpregnant status, we adjusted the myoinositol/D-chiroinositol doses by a 20% increase to the previously established doses used in a nonpregnant obese mouse model (myoinositol: 6 mg/ mL). 13, 14 Myoinositol and D-chiroinositol were purchased from Sigma Chemicals (St Louis, MO).
The treatment was maintained until term gestation (gestational day 18 of pregnancy), when dams were killed. Pregnant mice were single housed to be able to carefully evaluate water intake and consequently the daily dose of myoinositol/D-chiroinositol. Daily water consumption was estimated by subtracting the total amount of water left in the bottle from the initial amount supplied. On average, pregnant mice drink 5 mL/day, so myoinositol/ D-chiroinositol daily consumption was approximately 36/0.9 mg of, respectively, myoinositol/D-chiroinositol per day per mouse.
At term gestation, the metabolic profile of the metabolic-like syndrome and obese pregnant dams were obtained including the following: systolic blood pressure, a glucose tolerance test, maternal gestational weight gain, and serum levels of metabolic biomarkers relevant to diabetes and obesity. Damns were then killed and pups and placentas weights and numbers collected.
Blood pressure measurement Systolic blood pressure measurements were always taken on gestational day 18 in the morning at the same time using a calibrated, 8-chamber, tail-cuff system (CODA; Kent Scientific, Torrington, CT). Dams were kept warm using a warming pad. Mice underwent an initial 10 cycles of acclimatization period; blood pressure was then monitored and recorded over 10 new cycles. Systolic blood pressure averaged of the last 10 cycles was used for the final blood 
MLS and obesity mice models scheme
For the MLS mouse model, maternal (Mat; eNOS e/þ ) heterozygous females (gray mouse), with mild hypertension, were placed on a high-fat diet for 4 weeks to develop an MLS phenotype. For the obesity mouse model, wild-type CB57 females (white mouse) were placed on a high-fat diet for 4 weeks to induce an obese phenotype. Both animal models were then bred with wild-type normotensive males and starting from gestational day 1 were allocated either to MI/DCI treatment or water as placebo until term gestation when the experiments were performed, as displayed in the scheme.
DCI, D-chiroinositol; eNOS, endothelial nitric oxide synthase; HDL, high-density lipoprotein; MI, myoinositol; MLS, metabolic-like syndrome; WT, wild type. ajog.org SMFM Papers pressure measurement and utilized for data analysis. 25, 26 Glucose tolerance test Pregnant dams on gestational day 18 underwent a glucose tolerance test after being fasting for 6 hours. Mice received 1.0 g/kg of glucose intraperitoneally, and serial blood glucose levels, via a tail nick at 0, 15, 30, 60, and 120 minutes, were immediately determined with the AccuChek Aviva blood glucose meter system (Roche Diagnostics, Indianapolis, IN) after glucose administration. Glucose levels and the area under the curve were compared between the metabolic-like syndrome and obese pregnant mice treated with myoinositol/Dchiroinositol and identical nontreated mice.
27
Serum metabolic panel Blood samples were obtained as soon as animals were killed by heart puncture. Serum levels of metabolic biomarkers relevant to diabetes and obesity such as glucagon, insulin, leptin, ghrelin, gastric inhibitory peptide, glucagonlike peptide 1, and resistin were measured by a multiplex enzyme-linked immunosorbent assay (Bio-Rad Laboratories, Hercules, CA).
Statistical analysis
Results are expressed as mean AE SEM. All the data were analyzed using an unpaired t test with SigmaPlot 12. The analysis was done comparing metabolic-like syndrome myoinositol/ D-chiroinositoletreated pregnant mice vs metabolic-like syndrome nontreated (placebo) pregnant mice and obese myoinositol/D-chiroinositoletreated pregnant vs obese nontreated (placebo) pregnant mice. Numbers of pregnant mice per group were as follows: metabolic-like syndrome myoinositol/ D-chiroinositol treated, n ¼ 9; metabolic-like syndrome placebo treated, n ¼ 8; obese myoinositol/D-chiroinositol treated, n ¼ 8; and obese placebo treated, n ¼ 6. (Figure 1 ). 
Results

Food and water intake
Systolic blood pressure measurement
At term gestation, mean systolic blood pressure was lower in metabolic-like syndrome pregnant mice treated with myoinositol/D-chiroinositol compared with the placebo group (myoinositol/ D-chiroinositol: 138.52 AE 6.48 mm Hg vs placebo: 157.03 AE 7.79 mm Hg, P ¼ .04) (Figure 2A ). In the obese pregnant dams, there was no difference in systolic blood pressure between myoinositol/ D-chiroinositoletreated and placebo damns (myoinositol/D-chiroinositol: 143.18 AE 7.6 vs placebo: 150.09 AE 7.9) ( Figure 2B ).
Glucose tolerance
The glucose levels in the glucose tolerance test were lower in the metabolic-like syndrome pregnant mice treated with myoinositol/D-chiroinositol compared with placebo-treated mice at all time periods except for the 15 minute value ( Figure 3A) . To confirm, the area under the curve for the glucose tolerance test was lower in metabolic-like syndrome mice myoinositol/D-chiroinositole treated group (myoinositol/D-chiroinositol: 17512.5 AE 3984.4 vs placebo: 29687.14 AE 8258.7; P ¼.003). In contrast, in the obese pregnant dams, the glucose levels in the glucose tolerance test and the area under the curve were not different between myoinositol/D-chiroinositole treated and placebo-treated dams (myoinositol/D-chiroinositol: 23573.6 AE 4758.2 vs placebo: 25410 AE 5764.4) ( Figure 3B ). 
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Serum metabolic profile
Serum leptin levels were lower in the metabolic-like syndrome myoinositol/ D-chiroinositoletreated mice compared with the placebo-treated group (myoinositol/D-chiroinositol: 16985 AE 976.4 pg/dL vs placebo: 24181.9 AE 3128.2 pg/dL, P ¼ .045). No other differences were seen in the serum levels of the remaining metabolic biomarkers studied in the metabolic-like syndrome pregnant mice (Table) . No difference was found between obese myoinositol/ D-chiroinositoletreated and nontreated mice in any of the investigated metabolic biomarkers (Table) .
Weights
Gestational weight gain was not different between metabolic-like syndromee myoinositol/D-chiroinositoletreated and placebo mice (myoinositol/D-chiroinositol: 11.53 AE 0.9 g vs placebo: 11.6 AE 0.7 g) but was lower in the obese myoinositol/ D-chiroinositoletreated dams compared with the placebo-treated mice (myoinositol/D-chiroinositol: 10.9 AE 0.5 g vs placebo: 12.6 AE 0.6 g, P ¼ .04).
There were no differences between the pregnant metabolic-like syndrome myoinositol/D-chiroinositoletreated and placebo groups, respectively, in fetal weights and placental weights, as reported in the Table. Likewise, fetal and placental weights did not differ between myoinositol/D-chiroinositoletreated and placebo obese pregnant mice (Table) . Furthermore, no differences were found regarding the number of pups born from dams with metabolic-like syndrome or obese either treated or nontreated myoinositol/D-chiroinositol.
A summary of all experiments results is reported in Figure 4 .
Comment
We found that myoinositol/Dchiroinositol supplementation in pregnant mice with metabolic-like syndrome phenotype had improved blood pressure, glucose tolerance, and leptin levels. However, in obese pregnant mice, myoinositol/D-chiroinositol treatment prevented maternal increased weight gain associated with a high-fat diet but did not affect maternal glucose tolerance, blood pressure, and the metabolic markers related to diabetes.
Our findings therefore support the rationale for the use of combined myoinositol/D-chiroinositol supplementation in pregnancies complicated by metabolic syndrome but not by obesity alone in these animal models. Inositols are Food and Drug Administratione approved supplements 28 with a potential role in improving metabolic profile in metabolic syndrome. It is well established that metabolic syndrome traits, such as obesity and insulin resistance, during pregnancy have a negative impact on the pregnancy and on the metabolic and cardiovascular future health of the mother and the offspring. [4] [5] [6] [7] 29 Therefore, the potential of a new nonpharmacological approach as a preventive and therapeutic agent is clinically relevant because appropriate preventive strategies for metabolic syndrome in pregnancy have not yet been identified.
Previous human studies focused either on gestational diabetes prevention/therapy [15] [16] [17] [18] [19] or on metabolic syndrome associated with menopause 30, 31 or polycystic ovary syndrome, [32] [33] [34] whereas to the best of our knowledge, this is the first study to investigate inositols' combination effect in a metaboliclike syndrome and obese pregnant mouse model. Four human studies reported on the efficacy of myoinositol supplementation during pregnancy to prevent gestational diabetes in patients at risk because of family history, obesity, or polycystic ovary syndrome. [15] [16] [17] [18] In addition, 1 prospective randomized trial demonstrated a therapeutic role of myoinositol in women with diagnosed gestational diabetes showing that myoinositol in second trimester reduced homeostatic model assessment resistance and adiponectin concentrations compared with controls. 19 Similarly, in nonpregnant women with polycystic ovary syndrome [32] [33] [34] and postmenopausal women, 30, 31 myoinositol was shown to reduce insulin resistance and improve cardiovascular risk parameters (reduction in blood pressure, total and low-density lipoprotein-cholesterol, triglycerides, and enhancement of the highdensity lipoprotein-cholesterol). Our study reveals that inositol supplementation improved systolic blood pressure and glucose tolerance in pregnancies Glucose Tolerance Test (mg/dL) in MLS and obese pregnant mice Glucose levels in metabolic-like syndrome pregnant mice (A) and obese pregnant mice (B) at term gestation with and without MI/DCI treatment. Glucose levels were significantly lower in MI/DCI treated mice with MLS compared with nontreated animals at all time periods except for the 15 minutes. In obese mice the GTT was not different between MI/DCI-treated and nontreated animals. Significance is indicated on the figure. Asterisk indicates a value of P < .05.
DCI, D-chiroinositol; GTT, glucose tolerance test; MI, myoinositol; MLS, metabolic-like syndrome. The lack of effect in the obese pregnant mice could be due to the short period of high-fat diet exposure leading only to weight gain but not to metabolic abnormalities severe enough to reveal effects of myoinositol/D-chiroinositol supplementation. In fact, according to the literature, 4 weeks of high-fat diet exposure should be sufficient to develop a diet-induced obesity phenotype 23 ; however, several animal studies reported a longer period of high-fat diet exposure, up to 12 weeks, to manifest metabolic abnormalities and an inositol effect. 13 Moreover, the lack of effect in obese pregnant mice could be due to different mechanistic pathways involved.
We speculate that myoinositol/ D-chiroinositol treatment improves glucose tolerance in metabolic-like syndrome pregnant mice but not in the obese mice, possibly involving the nitric oxide nitric oxide pathway, which is known to be defective in our metaboliclike syndrome model, but not in the obese one. 21, 35 The exact molecular mechanisms of action of myoinositol and D-chiroinositol have not yet been fully elucidated. It has been shown that potential mechanisms by which the inositols might act is by improving endothelial function in decreasing radical oxidative stress, enhancing endothelial nitric oxide synthase and nitric oxide activity. 36 This endothelial nitric oxide synthase e/þ heterozygous mouse manifests metabolic-like syndrome, probably because of the lack of endothelial nitric oxide synthase associated with an obesogenic diet during pregnancy. The metabolic abnormalities seen in this model of metabolic-like syndrome might be a consequence of an endothelial dysfunction leading to hyperinsulinemia, insulin resistance, and increased blood pressure. Thus, this mouse model of metabolic-like syndrome seems very well suited to benefit from inositol supplementation, which aims at restoring endothelial function. Indeed, in our obese pregnant mouse model, an obesogenic diet alone and for FIGURE 4 Results summary Pregnant mice with the MLS phenotype treated with MI/D-chiroinositol during pregnancy have improved blood pressure, glucose tolerance, and leptin levels compared with nontreated mice. In obese mice instead, MI/DCI treatment prevented maternal increased weight gain associated with a high-fat diet but did not affect maternal insulin resistance and blood pressure. a short period of time does not seem to lead to such an endothelial dysfunction for which inositol supplementation could show a target effect. In our study leptin levels were improved by myoinositol/ D-chiroinositol treatment in metaboliclike syndrome pregnant mice, which is consistent with previous studies that showed decreased circulating leptin concentration after 16 weeks of myoinositol treatment in women with polycystic ovary syndrome. 12, 37 The exact mechanism by which myoinositol/ D-chiroinositol reduces leptin level remains unclear. Leptin controls energy balance and body weight by regulating neuronal activity in the hypothalamus. 38 It is possible that myoinositol/Dchiroinositol improved leptin resistance through either reductions in circulating leptin levels or the up-regulations of receptors mediating leptin's action to the brain, which needs further investigation. Furthermore, in our study, maternal gestational weight gain was significantly reduced in the obese mice after myoinositol/D-chiroinositol treatment, in agreement with previous studies on gestational diabetes patients. 15, 39 In both obese and metabolic-like syndrome models, pups and placental weights did not differ between myoinositol/ D-chiroinositoletreated and placebo animals.
These findings are in contrast to others that found a reduction in hyperglycemia-related complications, such as fetal macrosomia, after myoinositol supplementation in women at risk for gestational diabetes for a family history of type 2 diabetes 16 or elevating fasting glucose levels 15 ; however, again this could be due to a difference in the duration of a high-fat diet or to the fact that we evaluated the average weights of litters and placentas independently from their genotype (endothelial nitric oxide synthase e/þ heterozygous, 25%, or wild type, 75%). Study strengths are the following: (1) to the best of our knowledge, this is the first time that combined inositols (myoinositol/D-chiroinositol) have been evaluated as a mixture rather than single compounds during pregnancy and (2) and furthermore being used in a metabolic-like syndrome mouse model during pregnancy. Indeed, diet-induced obesity could be considered a less severe degree of the same metabolic disease that ultimately leads to metabolic syndrome. Therefore, the thorough investigation of inositol in the presence of a spectrum of components of metabolic syndrome, rather than obesity alone, allows for the identification of the best target population for myoinositol/D-chiroinositol treatment. Moreover myoinositol and D-chiroinositol have shown different concentrations at the tissue level 40, 41 and different roles in the whole cell, 11, 20 leading to the conclusion that both of them should be used in a synergistic action for the purpose of better treatment efficacy in metabolic diseases. 20 Unfer and colleagues 20, 42 performed dose-response studies identifying the physiological plasma ratio of myoinositol and D-chiroinositol equal to 40:1, which was proven to be the most effective in polycystic ovary syndrome overweight patients with metabolic abnormalities, but it has never been studied in pregnancies with metabolic abnormalities.
The main weakness of our study is that we did not investigate the effect of myoinositol/D-chiroinositol on the lipid profile, which is an important feature of metabolic syndrome. We also did not evaluate the nitric oxide pathway as well as the inositol phosphoglycans intracellular mediators as possible mechanisms involved in the myoinositol/ D-chiroinositol actions to elucidate our results. Moreover, in our study we did not plan to evaluate the combined myoinositol/D-chiroinositol effect in physiological uncomplicated pregnancies, nor did we plan to evaluate the effect of myoinositol or D-chiroinositol alone.
Future studies need to be performed to investigate the effect of myoinositol/ D-chiroinositol treatment on long-term maternal health and in the offspring born to metabolic syndrome and obese pregnancies to identify a possible role of inositols on metabolic fetal programming. Undoubtedly, further studies are warranted to fully elucidate the molecular pathways triggered by myoinositol and D-chiroinositol and to define the ideal timing (before conception, during pregnancy, and/or postpartum) dose and the combination of inositol stereoisomers of such a supplementation. n
